NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDOMET (methyldopate hydrochloride) is an injectable antihypertensive agent approved in 1962 that acts as a centrally-acting alpha-2 adrenergic agonist to reduce blood pressure. It is used for acute hypertensive episodes and hypertensive crisis management in hospital and clinical settings. The drug works by inhibiting norepinephrine synthesis and reducing sympathetic nervous system activity.
LOE Approaching
As a legacy injectable antihypertensive approaching loss of exclusivity with moderate competitive pressure (30%), this product likely supports a small, maintenance-focused team focused on preserving market share in acute care settings.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALDOMET offers limited career growth opportunities given its LOE-approaching status and minimal linked job openings (0 current roles). Working on this product suits professionals seeking defensive commercial strategy, hospital channel expertise, or regulatory compliance experience in a mature legacy asset rather than innovation-driven roles.
Brand ManagerField Sales Representative
Worked on ALDOMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.